Vertex Pharmaceuticals Incorporated (VRTX) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Vertex Pharmaceuticals Incorporated (VRTX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Vertex Pharmaceuticals Incorporated, analysts forecast revenue rising from $11.98B in 2025 to $20.77B in 2030; the average estimate for 2030 earnings per share is $33.79; with published estimates ranging from $32.23 to $35.36; 21 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Vertex Pharmaceuticals Incorporated (VRTX) forecast — frequently asked questions
What is the analyst price target for Vertex Pharmaceuticals Incorporated?
Analysts covering Vertex Pharmaceuticals Incorporated (VRTX) have a consensus price target of $580.20, 8.5% above the current price of $534.85. Published targets range from $350.00 to $665.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Vertex Pharmaceuticals Incorporated's earnings?
The average analyst estimate for Vertex Pharmaceuticals Incorporated (VRTX) earnings per share in 2030 is 33.79, with individual estimates between 32.23 and 35.36.
How much revenue is Vertex Pharmaceuticals Incorporated expected to make?
Analysts forecast Vertex Pharmaceuticals Incorporated (VRTX) revenue of $20.77B in 2030, based on 10 published estimates.
How many analysts cover VRTX?
21 analysts contribute estimates for Vertex Pharmaceuticals Incorporated (VRTX). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.